ImmunoGen Competitors and Similar CompaniesClear all
ImmunoGen's competitors and similar companies include ADC Therapeutics and Ablynx.
 ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. |  ADC Therapeutics ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers. |  Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. | |
Founding Date | Founding Date 1981 | Founding Date 2010 | Founding Date 2001 |
Type | Type Public | Type Public | Type Subsidiary |
Tags | |||
Locations | Locations Waltham, US HQ | Locations Epalinges, CH HQ London, GB New Providence, US | Locations Gent, BE HQ |
Employees | Employees 277161% increase | Employees 1162% increase | Employees 1252% decrease |
Valuation ($) | Valuation ($) 8.7 b | Valuation ($) 295.9 m | Valuation ($) N/A |
Financial | |||
Revenue (est.) | Revenue (est.) $108.8m (FY, 2022) | Revenue (est.) $81.4m (FY, 2025) | Revenue (est.) €85.2m (FY, 2016) |
Cost of goods | Cost of goods $176k (FY, 2022) | Cost of goods $5.1m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $108.6m (FY, 2022) | Gross profit $76.3m (FY, 2025) | Gross profit N/A |
Net income | Net income ($222.9m) (FY, 2022) | Net income ($142.6m) (FY, 2025) | Net income (€1.1m) (FY, 2016) |
Funding | |||
Total funding raised | Total funding raised $ 56m | Total funding raised $ 526m | Total funding raised $ 498.8m |
For sources of this data, please see the company profile
View Company Profiles
ADC Therapeutics
HQ
Epalinges, CH
Employees
116↑ 2% increase
ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.
View companyAblynx
HQ
Gent, BE
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.
View company